Functional and biochemical data have suggested a role for the cytochrome P450 arachidonate monooxygenases in the pathophysiology of hypertension, a leading cause of cardiovascular, cerebral, and renal morbidity and mortality. We show here that disruption of the murine cytochrome P450, family 4, subfamily a, polypeptide 10 (Cyp4a10) gene causes a type of hypertension that is, like most human hypertension, dietary salt sensitive. Cyp4a10 -/-mice fed low-salt diets were normotensive but became hypertensive when fed normal or high-salt diets. Hypertensive Cyp4a10 -/-mice had a dysfunctional kidney epithelial sodium channel and became normotensive when administered amiloride, a selective inhibitor of this sodium channel. These studies (a) establish a physiological role for the arachidonate monooxygenases in renal sodium reabsorption and blood pressure regulation, (b) demonstrate that a dysfunctional Cyp4a10 gene causes alterations in the gating activity of the kidney epithelial sodium channel, and (c) identify a conceptually novel approach for studies of the molecular basis of human hypertension. It is expected that these results could lead to new strategies for the early diagnosis and clinical management of this devastating disease.
Introduction
Prevalence, complexity, and multiple medical and socioeconomic consequences make hypertension a major health challenge for most of the Western world (1) . While environmental factors and coexist ing conditions play a role in the development and progression of hypertension, segregation and linkage analyses indicate that mul tiple genetic factors contribute to its complex etiology (2-7). Fur thermore, clinical studies show that the cardiovascular and renal morbidity and mortality resulting from hypertension are markedly reduced by timely diagnosis and early clinical intervention (1) . As the kidneys play a central role in the control of body salt and fluid balance, they are frequent targets for the treatment of hypertension, especially those forms sensitive to dietary salt (2) (3) (4) (5) . However, since the molecular basis of prevalent forms of the disease remains uncer tain, its early diagnosis and treatment are largely symptomatic. It is expected that the identification of novel pathways/genes involved in blood pressure variations (3, 6, 7) will lead to new therapeutic targets and to improved diagnosis and prevention. Indeed, early detection and treatment are urgently needed to prevent the dangerous and profound consequences of untreated chronic hypertension.
The metabolism of endogenous arachidonic acid (AA) to epoxy eicosatrienoic acids (EETs) and 20hydroxyeicosatetraenoic acid (20HETE) by the epoxygenase and ωhydroxylase branches of the cytochrome P450 (P450) AA monooxygenase is well established (8, 9) as are the biological activities of these metabolites (9) (10) (11) . Earlier studies identified members of the P450 CYP2C and CYP4A gene sub families as functionally relevant AA epoxygenases and ωhydroxy lases, respectively (8) (9) (10) (11) , and implicated them in the control of renal function and blood pressure (9) (10) (11) . However, the unequivocal inter pretation of these studies is complicated by the in vitro nature of the functional data available (8) (9) (10) (11) and genetic complexity of the animal models studied (9) (10) (11) (12) (13) . Consequently, notwithstanding their poten tial clinical importance, the physiological role of these enzymes in blood pressure regulation remains ambiguous and in need of experi mental confirmation. We show here that a dysfunctional cytochrome P450, family 4, subfamily a, polypeptide 10 (Cyp4a10) gene causes a type of hypertension that is dietary salt sensitive and associated with alter ations in the activity of the renal epithelial sodium channel (ENaC).
Results

Disruption of the Cyp4a10 gene causes hypertension.
Mating and selec tion of germ line chimeras carrying a mutant Cyp4a10 allele were used to generate homozygous Cyp4a10 +/+ and Cyp4a10 -/-mice (from the progeny of an F2 cross of Cyp4a10 +/-heterozygous mice) in isogenic 129/SvJ backgrounds. Cyp4a10 -/-mice devel oped normally and lacked outward symptoms of disease or organ malformation. Light microscopy analysis of paraffinembedded kidney sections and analysis of renal function by measurement of plasma creatinine levels by HPLC (14) demonstrated that disruption of the Cyp4a10 gene had little or no effect on organ morphology (not shown) or renal function before or after ani mal salt loading (157 ± 7 and 168 ± 10; 161 ± 6 and 169 ± 9 mg creatinine/dl for wildtype and Cyp4a10 -/-mice fed normal or highsalt diets, respectively; n ≥ 4).
Measurements of systolic blood pressure in adult Cyp4a10 -/-and Cyp4a10 +/+ mice provided decisive evidence of a role for Cyp4a10 in blood pressure control (Table 1) . Compared with wildtype mice, male and female Cyp4a10 -/-mice showed significantly increased systolic blood pressure when measured by either the tail cuff meth od (Table 1) or a carotid artery catheter (15) (average increases of 27 and 22 mmHg for the systolic blood pressure of male and female mice, respectively; n = 11; SEM ≤ 10% of the mean). Male and female Cyp4a10 -/-mice were equally hypertensive (Table 1) , and their plas ma androgen levels and renal 20HETE synthase activity were com parable to those of normotensive Cyp4a10 +/+ mice (15) .
Hypertension in Cyp4a10 -/-mice is dietary salt sensitive. To explore the mechanism of the hypertensive phenotype, male Cyp4a10 -/-and Cyp4a10 +/+ mice were fed diets containing (w/w) either 0.05% (low salt), 0.3% (normal salt), or 8% NaCl (high salt) and, after 3 weeks, their systolic blood pressure, urine volume, and urine sodium and potas sium concentrations were measured. While dietary salt had no signifi cant effects on the blood pressure of wildtype animals ( Figure 1A ), Cyp4a10 -/-mice on normal or highsalt diets were severely hypertensive and became normotensive when fed lowsalt diets ( Figure 1A ). These saltinduced pressure changes were accompanied by reductions in uri nary output during 16hour collection periods ( Figure 1B ) and thus in the amount of sodium (43% ± 15%; 44% ± 7%; and 64% ± 5% of wild type mice on lowsalt, normal, and highsalt diets, respectively; n ≥ 14) and potassium (57% ± 0.6%; 52% ± 0.4%; and 79% ± 0.6% of wildtype mice on lowsalt, normal, and highsalt diets, respectively; n ≥ 14) excreted during this time period. Furthermore, nuclear magnetic reso nance measurements (16) showed that free fluid volumes in Cyp4a10 -/-mice fed normal salt were higher than those of matched Cyp4a10 +/+ controls (2.0% ± 0.1% and 1.5% ± 0.1% of body weight, respectively; wild type versus knockout, P < 0.002; n = 8). Taken together, these results show that a dysfunctional Cyp4a10 gene causes reduced sodi um and potassium excretion, fluid retention, and hypertension.
Disruption of the Cyp4a10 gene does not alter renal 20-HETE synthase activity. Pro and antihypertensive roles have been described for 20HETE and its CYP4A2 synthase (9) (10) (11) , and 20HETE has been characterized as a natriuretic eicosanoid and a renal vasoconstrictor (9) (10) (11) . The phenotypic analysis of Cyp4a14 -/-mice confirmed the hemodynamic properties of 20HETE (15) and identified Cyp4a12 as an androgenregulated prohypertensive 20HETE synthase (15) . Among the murine Cyp4a proteins (15, 17) , only Cyp4a12 showed significant 20HETE synthase activity (turnover: 6.7 ± 0.6, 1.0 ± 0.3, and ≤ 0.01 min -1 for Cyp4a12, 4a10, and 4a14, respectively; n ≥ 6). Northern blots and enzymatic assays showed that disruption of the Cyp4a10 gene had only limited effects on kidney Cyp4a12 expres sion (not shown) or 20HETE synthase activity (59 ± 3 and 54 ± 2 pmol/min/mg of microsomal protein for Cyp4a10 +/+ and Cyp4a10 -/-mice, respectively). These results indicated that hypertension in Cyp4a10 -/-mice was unrelated to changes in kidney 20HETE bio synthesis and its effects on renal hemodynamics (15) .
Cyp4a10 -/-hypertension is amiloride sensitive. Within the P450 derived metabolites of AA, the EETs have attracted special atten tion because of their multiple vasoactive, transport, and antihy pertensive properties (8) (9) (10) (11) . Thus, for example, earlier studies demonstrated that renal EET biosynthesis was sensitive to dietary salt intake (18) , that inhibition of renal epoxygenase caused salt sensitive hypertension (19) , and that hypertensive Dahl saltsen sitive rats showed reductions in kidney epoxygenase activity and urinary EET excretion (19) . Moreover, studies with isolated rabbit collecting ducts (CDs) suggested a role for the EETs and the P450 epoxygenases in distal sodium excretion (8, 9, 20) and pointed to ENaC as their molecular target (21) . Amiloride and its analogs pro mote sodium excretion and potassium sparing by selective inhibi tion of ENaC (22) . To determine the contribution of ENaC dys function to the saltsensitive Cyp4a10 -/-hypertensive phenotype, we monitored the blood pressure of Cyp4a10 +/+ and Cyp4a10 -/-mice on normal salt diets daily, before and after the sequen tial administration in the drinking water of either amiloride, amiloride in 2% NaCl, or 2% NaCl alone. Within days of adminis tration, amiloride normalized the blood pressure of hypertensive Cyp4a10 -/-mice to levels comparable to those of wildtype mice ( Figure 2 ). Cyp4a10 -/-mice on amiloride remained normotensive, even when administered 2% salt water (Figure 2) . Importantly, the effects of amiloride on Cyp4a10 -/-mice were reversible since, upon its removal, the hypertensive phenotype of the Cyp4a10 -/-animals was fully restored (Figure 2 ). In contrast, amiloride alone or in combination with 2% NaCl caused minor changes in the blood pressure of Cyp4a10 +/+ mice ( Figure 2 ). These results indicate that ENaC dysfunction accounts for the Cyp4a10 -/-hypertensive pheno type and suggest that products of the P450 AA monooxygenases could participate in the regulation of ENaC gating activity. 
Figure 1
Hypertension in Cyp4a10 -/-mice is salt sensitive. Groups of male Cyp4a10 +/+ (WT) (white bars) and Cyp4a10 -/-(KO) (black bars) mice were fed low-salt, normal, or high-salt diets (containing 0.05, 0.3, or 8% NaCl w/w), respectively. After 3 weeks, their systolic blood pressure (in mmHg) (A) and their urine output during 16-hour collections (B) were measured. Values are averages ± SEM calculated from at least 14 (low salt), 15 (normal salt), and 24 (high salt) mice. # P < 0.05; *P < 0.001, significantly different from wild type. The blood pressure of Cyp4a10 +/+ and Cyp4a10 -/-mice on low-salt diets was not significantly different.
Cy4a10 -/-hypertension in mice is associated with changes in ENaC activity.
A recent report (21) provided an explanation for the reported transport effects of the EETs in the distal nephron (8) (9) (10) (11) by show ing that in rat cortical CDs, (a) AA and 11,12EET, an epoxygen ase metabolite, inhibit ENaC activity; (b) AAelicited inhibition of ENaC requires its conversion to EETs; (c) 11,12EET is formed by CDs, and the CYP2C23 epoxygenase is present in this segment; and (d) ENaC inactivation by 11,12EET is unique since indomethacin, a cyclooxygenase inhibitor, had no effect on the AAinduced respons es, nor did 20HETE mimic the EET response. We therefore studied the effects of AA and of 11,12EET on the ENaC activity of cortical CDs from Cyp4a10 +/+ and Cyp4a10 -/-mice. Under control condi tions, we observed significant differences in ENaC basal activity between Figure 3A ). This is similar to what is observed in Liddle syndrome, a Mendelian form of human hypertension in which mutations in the b and g sub units of ENaC cause gain of function and increased sodium cur rents (3) (4) (5) (6) (7) 23) . Furthermore, while AA effectively inhibited ENaC gating in wildtype mice ( Figure 3 , B and C), it had only marginal effects on the knockout mice ( Figure 3 , A and C), suggesting that these animals had impaired epoxygenase activity. A role for the EETs and the AA epoxygenase in regulating murine ENaC activity was indicated by the demonstration that 11,12EET inhibits the channel, regardless of Cyp4a10 genotype ( Figure 3 ). In summary, the results shown in Figure 3 provide a mechanistic explanation for the saltsensitive nature of the Cyp4a10 -/-hypertensive pheno type, extend the roles postulated for 11,12EET in regulating sodi um excretion to the murine nephron, and document a functional role for the AA monooxygenases in sodium plasma homeostasis. Thus, genetically determined (Cyp4a10 disruption) reductions in EET biosynthesis or selective epoxygenase inhibition ( Figure 3C ) (21) equally abrogate the AAmediated inactivation of ENaC and result in increased inward sodium flux.
Cy4a10 -/-hypertension in mice is associated with changes in renal EETs.
To explore the role of the EETs in the in vivo regulation of ENaC activity and in the Cyp4a10 -/-hypertensive phenotype, we first measured by mass spectral methods (24) the EETs present endog enously in the kidneys or in urine collected from Cyp4a10 +/+ and Cyp4a10 -/-mice. While no major differences were observed in EET organ levels, the Cyp4a10 -/-mice showed significant reductions in the total amounts of epoxygenase products excreted into their urine during a 16hour collection period (5.1 ± 0.7 and 3.2 ± 0.6 ng for wildtype and knockout mice, respectively; n = 4). These results, qualitatively similar to what has been reported for hypertensive Dahl saltsensitive rats (19) , suggested that a reduced renal EET biosynthetic capacity could be responsible for the ENaC dysfunc tion observed in hypertensive Cyp4a10 -/-mice ( Figure 3) .
It is now well established that the AA epoxygenases belong to the cytochrome P450 2 gene family (8) and that members of the Cy2c and Cyp2j gene subfamily are expressed in the mouse kidney (25) (26) (27) . Extensive chemical, biochemical, and immunological evidence show that CYP2C23 is (a) the predominant epoxygenase present in the rat kidney (28, 29) , (b) the P450 isoform responsible for the regio and stereochemical properties of the EETs generated by the kidney microsomal proteins (28, 29) , (c) the renal epoxygenase induced in response to dietary salt loading (29) , and (d) the CYP2C epoxygen ase expressed in the rat CD (21) . From a cDNA library, we cloned and expressed Cyp2c44, the mouse homologue of CYP2C23 (28) (88% amino acid sequence identity) and demonstrated that purified recombinant Cyp2c44 metabolizes AA to 11,12EET as its major product (65% of total), with stereoselectivities similar to those previ ously reported for CYP2C23 (28, 29) and Cyp2c44 (27) . However, a
Figure 2
Amiloride normalizes the blood pressure of hypertensive Cyp4a10 -/-mice. The systolic blood pressure of male Cyp4a10 -/-(discontinuous line) and Cyp4a10 +/+ (continuous line) mice (n = 5 each) on diets containing 0.3% NaCl (w/w) were monitored before (days 1 to 4) and after the sequential administration of drinking water containing amiloride (days 8 to 21), a mixture of amiloride and 2% NaCl (days 22 to 28), and finally 2% NaCl alone (days 29 to 34). *P < 0.001 Cyp4a10 -/-versus amiloridetreated Cyp4a10 -/-mice. # P ≤ 0.001 Cyp4a10 -/-versus Cyp4a10 +/+ mice for all additional amiloride treatment regimes. **P < 0.001 Cyp4a10 -/-mice on water versus Cyp4a10 -/-mice on 2% salt water. study of the effects of dietary salt loading on kidney Cyp2c44 expres sion by Northern blot or realtime PCR quantification indicated that, while Cyp2c44 was the predominant Cyp2c form expressed in mouse kidney (not shown), salt loading caused variable and limited chang es in its expression levels in the kidneys of Cyp4a10 +/+ or Cyp4a10 -/-mice. Furthermore, an extended Northern blot and/or realtime PCR study of the effects of salt loading on the levels of Cyp2c29, Cyp2c38, Cyp2c40, Cyp2j5, and Cyp2j6 transcripts, all identified as potential renal AA epoxygenases (25) (26) (27) , yielded similar results.
To determine whether the experimental manipulation of kidney Cyp2c44 epoxygenase levels and EET biosynthesis normalizes the blood pressure of Cyp4a10 -/-mice and thus whether reductions in CD epoxygenase activity could be responsible for the hyperten sive phenotype, Cyp4a10 +/+ and Cyp4a10 -/-mice were administered Wyeth 14643 (Wy), a selective PPARα ligand (30, 31) , and its effects on kidney epoxygenase metabolite urine excretion, Cyp2c44 mRNA levels, and blood pressure determined. Published studies have shown that PPARα ligands induce renal CYP2C23 epoxygenase expression (32) and that they reduce blood pressure in rat models of saltsen sitive hypertension (10, (32) (33) (34) . To study the effects of Wy on the renal epoxygenase, we measured by liquid chromatography-tandem mass spectroscopy (LC/MS/MS) the levels of urinary EETs and dihy droxyeicosatrienoic acids (DHETs) before and after treating wild type and Cyp4a10 null mice with the PPARα ligand. Since DHETs result only from the hydration of precursor EETs, the combined con centrations of EETs and DHETs are a measure of renal epoxygenase biosynthetic capacity and urinary excretion. In Cyp4a10 +/+ mice, Wy treatment caused a 2.2fold increase in the urinary excretion of the AA 11,12epoxygenase metabolites (Table 2 ) and had a more limited impact on 8,9 and 14,15epoxygenase metabolite excretion (Table 2) . On the other hand, and while the overall activity of the renal AA epox ygenase of Cyp4a10 -/-mice is lower than that of wild type (Table 2) , Wy administration raised the overall excretion levels of epoxygenase metabolites by 2.0fold and increased their concentrations to levels similar to those found in the urine of wildtype animals (Table 2) . Furthermore, and as with wildtype mice, Wy was most effective in increasing the renal biosynthesis of 11,12EET (Table 2) , the EET regioisomer shown to be the most powerful regulator of ENaC gating activity (21) . As shown in Table 2 and consistent with the reported regioselectivity of the Cyp2c44 epoxygenase (27) , treatment of Cyp4a10 -/-mice with Wy also increased the urine levels of the 8,9 and 14,15AA epoxygenases (2.3 and 1.6fold increases, respectively) ( Table 2) . Finally, the levels of epoxygenase metabolites present in the urine provide an aver aging measure of overall renal EET biosynthesis and are of limited value in predicting the EET biosynthetic capacity of individual nephron segments. However, studies in dissected rat kidney CDs have demonstrated EET biosynthesis and CYP2C23 epoxygenase expression in this segment (21) . The detection sensitivity of current mass spectrometric methods precludes the analysis of EET biosynthesis in mouse nephron segments such as the CD, where ENaC activity is regulated by 11,12EET (Figure 3 ).
In parallel with the increases in epoxygenase metabolites shown in Table 2 , Wy treatment raised the concentrations of Cyp2c44 mRNA transcripts present in the Cyp4a10 +/+ kidney ( Figure 4 , A and C) and caused small but significant decreases in the animals' blood pressure ( Figure 4B ). On the other hand, the PPARα ligand effectively normalized the blood pressure of hypertensive Cyp4a10 -/-mice ( Figure 4B ) and raised their urine epoxygenase metabolites and kidney Cyp2c44 mRNAs to levels similar to or higher than those present in wildtype mice (Table 2 ) (Figure 4 , A and C). This association between an increase in renal Cyp2c44 expression and activity and a reduction in systemic blood pressure supports the antihypertensive functions proposed for the EETs (8-11) and points to the EETs and the AA epoxygenase as endogenous regulators of ENaC activity (20, 21) . The mechanism(s) by which the Wy regulates renal Cyp2c44 epoxygenase expression 
Figure 4
Wy normalizes blood pressure and Cyp2c44 expression in Cyp4a10 -/-mice. Male Cyp4a10 +/+ (WT) and Cyp4a10 -/-(KO) mice were administered water (white bars) or a 0.02% solution of Wy (black bars) as drinking water, and after 10 days, systolic pressure and kidney Cyp2c44 expression were measured. (A) Real-time PCR quantification of Cyp2c44 mRNA levels normalized using the b-actin mRNA as reference. Shown are averages ± SEM calculated from 6 experiments. *P < 0.0005; # P < 0.003, significantly different from untreated controls. (B) Systolic blood pressure (in mmHg). Values are averages from groups of 5 mice each. **P < 0.001, significantly different from untreated knockout; ## P < 0.01, significantly different from untreated wild type. (C) mRNAs from control (CT) and Wy-treated (Wy) wild-type and knockout (KO) mouse kidneys were analyzed by Northern blot using a Cyp2c44-specific probe. Loadings were normalized using a b-actin probe.
are under study. Nonetheless, the parallel upregulation by Wy of the kidney acylCoA oxygenase gene (not shown), a known PPARα target (30, 31, 35) , suggests a role for this nuclear receptor in the process.
Discussion
The studies summarized above provide unequivocal evidence of a physiological role for the P450 AA monooxygenases and for the Cyp4a10 gene in particular in the control of ENaC function, renal Na + transport, and, ultimately, systemic blood pressure. The Wy and amiloridesensitive nature of the Cyp4a10 -/-hypertensive phe notype, and the documented association of the pressure effects of these compounds with an upregulated AA epoxygenase expression or ENaC inhibition, point to a causeeffect relationship among a Cyp4a10mediated regulation of CD epoxygenase levels, EET biosynthesis, and ENaC activity. While the mechanism by which products of the Cyp4a10 gene regulate renal epoxygenase expres sion remains to be defined, there is an established role for PPARα and its synthetic ligands in the control of P450 expression (30) and of fatty acid metabolism and lipolysis (31) . Recent studies have identified several antihypertensive and cardiovascular protective effects resulting from PPARα activation and/or the administration of synthetic PPARα ligands (10, (32) (33) (34) . Furthermore, it has been reported that some of the hypotensive effects of PPARα ligands are associated with changes in the renal expression of CYP4A (10) or CYP2C (32) isoforms, which are known targets for PPARαdepen dent transcriptional control (30, 31) , and concerted AA oxidation by CYP4A and CYP2C isoforms generates AA epoxy alcohols that are highaffinity PPARα ligands (35) , suggesting that a regulatory loop involving these P450 isoforms may be involved in endogenous PPARα activation (35) . As an extension of the studies discussed, we are proposing that a dysfunctional Cyp4a10 gene alters PPARα ligand biosynthesis and that this impairs the PPARαdependent expression of a CD Cyp2c epoxygenase and results in reduced CD EET synthesis and increased ENaC gating.
The CD contributes to the fine tuning of plasma sodium concen trations, and sodium reabsorption by the CD ENaC is a ratelimit ing step for this physiologically vital function (2, 3, 23, (36) (37) (38) . Dis orders in which gainoffunction mutations in ENaC cause severe hypertension have illustrated the importance of this channel in the regulation of human blood pressure (2, 3, 23, 36) . Like most ion channels, ENaC function can be regulated by changes in gat ing properties or membrane density, and the role of aldosterone in regulating apical channel expression in the CD is well established (2, 3, 23, 36-38) . Nonetheless, the early responses to aldosterone occur prior to detectable changes in ENaC mRNA or protein levels and involve proteins thought to be responsible for ENaC trafficking and/or activity, including a serum and glucocorticoidinducible kinase (SGK), Nedd42, Kras2, and channelactivating protease 1 (CAP1) (36) (37) (38) (39) (40) . Other than these hormonemediated changes, little is known regarding factors governing intrinsic ENaC gating activity and sodium currents except that an inositol phospholip id-binding regulatory region in the g subunit of ENaC was recently identified and characterized (41) . The nearly instantaneous nature of the EET effects on ENaC activity ( Figure 3, A and B) suggests a role for these eicosanoids in the realtime regulation of this channel and explains their reported effects on sodium transport (20, 21) .
The phenotypic characterization of Cyp4a10 -/-mice and that reported for Cyp4a14 -/-mice (15) illustrate the key roles that these 2 genes have in the regulation of tubular function (Cyp4a10) and renal hemodynamics (Cyp4a14) (14) and provide a molecular basis for future studies of the pro and antihypertensive effects associ ated with 20HETE and EETs (9-11), respectively. It is of particular interest that both murine Cyp4a genes exert these renal and pres sure effects by controlling the transcriptional activation of alter nate P450 genes coding for either 20HETE or EET synthases.
Based on the results discussed, we propose that under conditions of balanced salt intake and excretion, locally generated EETs participate in nonstimulated ENaC gating and the regulation of distal sodium reabsorption. Dietaryinduced increases in plasma sodium cause com pensatory volume changes and rapid and delayed epoxygenasemedi ated responses ( Figure 5 ). The rapid phase involves phospholipase dependent AA release and metabolism to EETs. The delayed phase requires an upregulated AA epoxygenase expression and increased EET synthase activity in the CDs ( Figure 5 ). Augmented EET levels cause an EETmediated inactivation of ENaC, a reduction in inward sodium transport, and increased sodium excretion ( Figure 5 ). Reductions in epoxygenase expression or activity increase ENaC dependent sodium reabsorption and, to maintain plasma sodium levels within physiologically compatible levels, there is increased water retention and expansion of the plasma volume. These epoxy genasemediated increases in ENaCdependent sodium reabsorption and the attendant changes in plasma volume result in increased sys temic blood pressure ( Figure 5 ) and, ultimately, hypertension. The proposal in Figure 5 is consistent with the normotensive effects of amiloride and Wy on Cyp4a10 -/-mice as well as the ENaC normal izing effect that 11,12EET has on the CDs of these animals.
The demonstrations of altered tubular transport in saltsensitive hypertensive Cyp4a10 -/-mice offer new insights into the mechanisms by which the kidney regulates sodium excretion and suggest that interventions resulting in increased kidney epoxygenase expression (32) or EET concentrations (42, 43) could serve as the basis for the development of future antihypertensive therapies. Since an impor tant subset of human hypertensives are salt sensitive (1-5) and this has been associated with alterations in sodium excretion (2-5), we
Figure 5
Roles proposed for the epoxygenase regulation of renal sodium reabsorption and plasma volume. Ascending and descending arrows denote increases or decreases in boxed parameters, respectively. Dashed arrows are used to indicate the participation of Cyp4a10 gene product(s) in the regulation of kidney Cyp2c44 levels.
propose the human homologues of Cyp4a10 as candidate genes for studies of their role in hypertension. Recent clinical data indicating a role for 20HETE in human saltsensitive hypertension (44) and the identification of an association between a human CYP4A11 gene variant and essential hypertension (45, 46) lend further support to this proposal. Finally, synthetic PPARα ligands have been utilized as hypolipidemic agents with limited side effects. Based on the studies reported here and elsewhere (32) (33) (34) , the evaluation of their poten tial antihypertensive effects in humans seems warranted.
Methods
cDNA cloning, expression, and enzymatic analysis. The Cyp4a10, 4a12, 4a14 and 2c44 cDNAs were cloned and expressed in E. coli (14, 16, 47) (the Cyp4a10 gene sequence is available at www.ncbi.nih.gov; MGI:88611, 13117). North ern blot analyses of RNAs isolated from the kidneys of Cyp4a10 -/-mice revealed the presence of transcripts recognized by the Cyp4a10 probe in these animals. RTPCR cloning using Cyp4a10 forward (5′TTGCAGA CAGCCTCTCTGGCTTCC3′) and reverse primers (5′CTCGAGGTTA CAGACTCTTCTC3′) and sequence analysis showed that these RNA tran scripts originated from a Cyp4a10 pseudogene and that, compared with the Cyp4a10 mRNA, they contained several single nucleotide replacements, a 429 bp intronic insertion, and a 17 bp deletion at nucleotide 1255 (from the ATG translation initiator) that causes a frame shift and would generate a protein lacking a heme prosthetic group. mRNA expression levels were estimated by Northern blot (15) or realtime quantitative PCR using a BioRad iCycler iQ instrument (BioRad) and the manufacturer's reagents and software (Gene Expression Analysis for iCycler iQ Real Time PCR Detection System). Total RNAs were isolated from whole mouse kidneys using the TRIzol Reagent (Invitrogen Corp.) and, in some experiments, purified by oligo(dT) chromatography. For realtime quantitative PCR, kidney reverse transcriptase products were amplified using the follow ing primer pairs: Cyps 2b9, 2b10, and 2b19: 5′TGCTCCACGAGACTACATT GA3′ and 5′GTACTTGAGCATGAGCAGGA3′; Cyp2c29: 5′TGTCCTG GAAGTCATCACAAA3′ and 5′TTGTTCAATGTGGTTTACCTGTT3′; 2c37: 5′CTGCTTTCCACACTGGACAC3′ and 5′CAGGTCCATATCATCA CAGCA3′; Cyp2c38: 5′CCCCCAGGTTTTTATTCACC3′ and 5′GCATA AGGGCTCAGACAACTG3′; 2c39: 5′CCTCCTTTATTGCCTTCTGC3′ and 5′TGCATTTGTGCTATAACTCCAGA3′; Cyp2c40: 5′CATGGATAT GACCCCCAAAC3′ and 5′TGGGACTGGGTTAAATGAGG3′; Cyp2c44: 5′TGCTACCTAGGCCAGAAACA3′ and 5′GATGAGGGCCTTGT GGATCT3′; Cyp2j5: 5′CCTGCTCACATGAGAAGTGATAG3′ and 5′GATGATAAGGTATGTCACTGGACAC3′; Cyp2j6: 5′GGTTGCT CACACGAGAGAAG3′ and 5′GCATGCCACTGAGCTCATAA3′; bactin: 5′ AGGTGACAGCATTGCTTCTG3′ and 5′AGGGAGACCAAAGCCTTCAT 3′. Averaged Cyp2c and bactin fluorescence threshold crossing cycle calculated from a PCR baseline subtracted from curve fit (Cτ) values were utilized to calculate bactin normalized mRNA expression levels.
Kidney microsomes were isolated and incubated with [1 14 C]AA (100 mM) and NADPH (1 mM) as described (48) . Purified recombinant P450s (0.1 mM) were incubated with purified rat P450 reductase (1 mM) and dilauroylphos phatidylcholine (50 mg/ml) prior to the addition of AA (75 mM) and NADPH (1 mM). Cyp4a proteins were reconstituted in the presence of cytochrome b5 (15, 48) (0.1 mM). Products were quantified as published (48) . The creatinine concentrations of plasma samples obtained from Cyp4a10 +/+ and Cyp4a10 -/-mice fed solid diets containing normal salt (0.3% NaCl w/w) or high salt (8% NaCl w/w for 14-16 weeks) were determined as reported (14) .
Construction of the Cyp4a10-targeting vector. Overlapping clones encoding all Cyp4a10 exons were isolated from a 129/SvJ mouse BAC genomic library (Invitrogen Corp.). A linearized pNTK targeting vector containing an Nco1 flanked Cyp4a10 gene segment in which exon 3 and part of exon 4 were replaced by a neomycin cassette was electroporated into TL1 129/SvEv Tac mouse ES cells. Recombinant ES cells were identified by Southern blots of Acc1 digests using a 1.0 kb Cyp4a10 probe coding for exon 1 and segments of its flanking intron and 5′ upstream sequences. The neomycin replacement removed exon 3 of the Cyp4a10 gene, interrupted inframe translation at exon 4, and eliminated a diagnostic AccI site, used for genotype analysis. Two ES clones carrying a Cyp4a10 mutant allele (IE5 and ID12) were utilized for the generation of germ line chimeras. Mice were fed commercial solid diets con taining 0.05, 0.3, or 8% NaCl (w/w) and allowed free access to water. Amiloride was administered in the drinking water and its concentrations adjusted to a daily dose of approximately 2 mg/kg of body weight. Wy was administered as a 0.02% w/v solution in the drinking water. Animal experiments were per formed in accordance with NIH policies and approved by the Vanderbilt Uni versity Medical Center Institutional Animal Care and Use Committee.
Blood pressure measurements. Systolic blood pressure of conscious 12 to 20weekold mice was measured at an ambient temperature of 23°C using a tail cuff blood pressure analyzer (model 178; IITC Inc.). Prior to measurement, animals were exposed to the environment and instrument on a daily basis for at least 7 days. The blood pressure of trained mice was monitored for 30-40 min utes and final values obtained after 4 consecutive readings whose values were within ±5% of the mean. In some experiments, blood pressure was measured by means of a MicroRenthane tapered catheter (300-500 mm OD) inserted into the right carotid artery as described (15) . After phenotype confirmation with the Cyp4a10 -/-ID12 clone, all subsequent studies were done using the Cyp4a10 -/-IE5 line. Daily measurements of free fluid volume (16) were done at 10 am and at 3 pm for 3 consecutive days and in groups of agematched male Cyp4a10 +/+ and Cyp4a10 -/-mice (at least 8 animals each), using a Bruker Mini spec mq10 (Bruker BioSpin Corp.) nuclear magnetic resonance instrument. Urinary sodium and potassium were measured by flame photometry.
Analysis and quantification of urinary epoxygenase products. Overnight urine samples were collected from groups of 4-5 adult mice in flasks containing tri phenylphosphine (2-3 mg each) (30) . After adding synthetic [20 2 H3]-labeled 8,9; 11,12; and 14,15EET (5 ng each) and [5, 6, 8, 9, 11, 12 , and 14,15 2 H8]-labeled 8,9; 11,12; and 14,15DHET (5 ng each) as internal standards, the urine EETs and DHETs were extracted with acidified CHCl3/CH3OH (2:1) (24), purified by reverse phase HPLC as described (24) , and methylated by reaction with diazomethane in ethyl ether (24) . The resulting methylEETs and methylDHETs were quantified by LC/MS/MS using an Agilent Eclipse XDBC8 column (2.1 × 150 mm; 5 mm) connected to a TSQQuantum MS/MS spectrometer (Thermo Electron Corp.). EETs and DHETS were resolved using a linear solvent gradient that went from 80% CH3OH, 20% H2O containing 25 mM AgBF4 to 100% CH3OH containing 25 mM AgBF4 in over 10 minutes and at a flow of 0.2 ml/min. For analysis and quantification, we utilized col lisioninduced fragmentation of the methylEET 107 Ag adducts at m/z 441 and 444 (corresponding to the molecular ions of the biological sample and the internal standard, respectively) and of the methylDHET 107 Ag adducts at m/z 459 and 467 (corresponding to the molecular ions of the biological and the internal standard, respectively). Diagnostic selective product ion analysis was done at m/z 261, 247, and 287 for 107 Ag adducts of the methyl esters of 8,9, 11,12, and 14,15EET, respectively; at m/z 317, 34,7 and 329 for the ion fragments generated by the 107 AG adducts of the methyl esters of 8,9, 11,12, and 14,15DHET, respectively; and at m/z 323, 353, and 335, respectively, cor responding to the ion fragments originating from the corresponding 107 Ag adducts of the deuterated internal standards. Quantifications were done using isotope ratios and ion intensities versus mass calibration curves (24) .
CD isolation and electrophysiology. Male wildtype and Cyp4a10 -/-mice were fed lowsodium diets for 5-7 days. Cortical CDs microdissected from kid ney slices (1 mm thickness) were placed on an inverted microscope, super fused with HEPESbuffered NaCl (21) , and cut open to expose the apical membrane. Sodium currents were recorded and digitized as described (21) .
